Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00963339
Other study ID # US02
Secondary ID
Status Completed
Phase N/A
First received August 20, 2009
Last updated September 22, 2010
Start date September 2009
Est. completion date September 2010

Study information

Verified date September 2010
Source Notal Vision Ltd
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

The purpose of this study is to evaluate the usability of the Foresee Home device with intermediate AMD patients.


Description:

The AMD usability study is a prospective, longitudinal, multi-center, observational study of patients diagnosed with intermediate (dry) AMD who have been asked by their doctor to use the ForeseeHomeTM device to record the natural progression of their AMD, including conversion from the dry to wet stage.


Recruitment information / eligibility

Status Completed
Enrollment 54
Est. completion date September 2010
Est. primary completion date December 2009
Accepts healthy volunteers No
Gender Both
Age group 50 Years and older
Eligibility Inclusion criteria

- Subjects diagnosed as intermediate AMD in at least one eye

- Visual Acuity (VA) with habitual correction <20/60 in the study eye

- Qualified in the clinic to use the device

- Ability to speak, read and understand instructions in English

- Subjects with ability to comprehend and sign the informed consent/authorization

Exclusion criteria

- Evidence of macular disease other than AMD or glaucoma in the study eye

- Presence of any significant media opacity that precludes a clear view of the macular area as identified in the study eye by biomicroscopy

- Any non-macular related ocular surgery performed within 3 months prior to study entry in the target eye

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Device:
Foresee Home
Home Monitoring

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Notal Vision Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Successful unpacking and installation 3 months No
Primary Successful self tutorial performance 3 months No
Primary Ability of the subjects to operate the device as define by a successful test completion 3 months No
Secondary Evaluate the success rate of the interactive tutorial as defined by a reliable test result. 3 month No
See also
  Status Clinical Trial Phase
Recruiting NCT03963817 - Snapshot Camera for AMD
Recruiting NCT04929756 - Eye Movement Rehabilitation in Low Vision Patients
Completed NCT04779398 - Association of MPOD Values With Blue Light.
Terminated NCT03275753 - Visual Function Tests in Age-related Macular Degeneration
Recruiting NCT03609307 - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Phase 2/Phase 3
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Active, not recruiting NCT01943396 - Treatment of AMD With Rheohemapheresis /RHF/ Phase 4
Completed NCT00376701 - Combination Therapy for Age-Related Macular Degeneration. Phase 2
Recruiting NCT00347165 - Intravitreal Bevacizumab for Age-Related Macular Degeneration Phase 2
Completed NCT00800995 - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD) Phase 3
Completed NCT04689789 - OCTA and Retinal Angiomatous Proliferation
Completed NCT02567604 - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed NCT02173496 - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting NCT01991730 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients N/A
Active, not recruiting NCT01657669 - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Phase 4
Completed NCT00791570 - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy Phase 1
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Completed NCT00413829 - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) Phase 2
Completed NCT00358345 - PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization Phase 4